
Physitrack Q3 2024 - Soft short-term outlook

Redeye has updated its estimates and valuation following Physitrack's Q3 report. As anticipated, the quarter was soft due to software delays in the Wellness division, and a few more sideways quarters are expected for the division in the short term. Nonetheless, management is confident in the company's financial stability, with no anticipated capital raise. Our new fair value range is SEK8-72 (SEK9-72) per share, with a Base case of SEK23(30).

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Physitrack Q3 2024 - Soft short-term outlook](#)